Peter Bains

Currently, Peter James Jonathan Bains is Group Chief Executive Officer at Biocon Biologics (Thailand) Co. Ltd., Biocon Biologics Switzerland AG, Biocon Biologics South Africa (Pty) Ltd., and Biocon Biologics Spain SLU.
He is Non-Executive Chairman at ILC Therapeutics Ltd., Chief Business Officer & Non-Executive Director at MiNA Therapeutics Ltd. since 2020, Director at Mina (Holdings) Ltd. since 2014, and Non-Executive Director at Apterna Ltd. Formerly, he was President, Chief Executive Officer & Director at Nxera Pharma Co., Ltd. from 2016 to 2018, Group Chief Executive Officer at Biocon Ltd. from 2023 to 2025, Chief Executive Officer, Executive Director & MD at Syngene International Ltd. from 2025 to 2026, Non-Executive Chairman at Fermenta Biotech Ltd. from 2010 to 2018, Non-Executive Director at Phase4 Partners Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Syngene International Ltd. from 2016 to 2017, Independent Non-Executive Director at Kromek Group Plc in 2015, Director at Nxera Pharma UK Ltd., Director & Senior Vice President-Global Marketing at SmithKline Beecham Ltd., Director at Baines Peter Consulting, Independent Non-Executive Director at Mereo BioPharma Group Plc from 2015 to 2021, Director at Sosei R&D Ltd., Independent Non-Executive Director at Indivior Ltd. from 2019 to 2025, and SVP-International Commercial Development at GSK Plc.
Education includes an undergraduate degree from The University of Sheffield, conferred in 1979.